Perspectives on the future of bisphosphonate use in breast cancer patients
- 1 October 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 87-91
- https://doi.org/10.1053/j.seminoncol.2004.07.029
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?Cancer Treatment Reviews, 2004
- Should All Breast Cancer Patients with Symptomatic Bone Metastases be Treated with Bisphosphonates? The Case in SupportClinical Oncology, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- ‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overviewThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnnals of Oncology, 2003
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerBMJ, 2003
- Prevention and Treatment of Osteoporosis in Women With Breast CancerMayo Clinic Proceedings, 2000
- Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.British Journal of Cancer, 1998